Kamada (KMDA) Scheduled to Post Earnings on Wednesday

Kamada (NASDAQ:KMDA) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.06 per share for the quarter. Kamada has set its FY 2024 guidance at EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Kamada (NASDAQ:KMDA) last released its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.04. Kamada had a return on equity of 5.66% and a net margin of 5.81%. The company had revenue of $36.43 million for the quarter, compared to analyst estimates of $37.71 million. On average, analysts expect Kamada to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kamada Trading Down 1.4 %

NASDAQ:KMDA traded down $0.08 during midday trading on Monday, hitting $5.67. 2,952 shares of the company traded hands, compared to its average volume of 22,463. The firm’s fifty day moving average is $5.60 and its 200-day moving average is $5.49. Kamada has a 12-month low of $4.08 and a 12-month high of $6.53. The firm has a market capitalization of $325.91 million, a P/E ratio of 38.33 and a beta of 1.05.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Kamada in a report on Thursday, March 7th.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.